YU67501A - Farmaceutska kompozicija sa sadržajem tolperisona za oralno davanje - Google Patents

Farmaceutska kompozicija sa sadržajem tolperisona za oralno davanje

Info

Publication number
YU67501A
YU67501A YU67501A YU67501A YU67501A YU 67501 A YU67501 A YU 67501A YU 67501 A YU67501 A YU 67501A YU 67501 A YU67501 A YU 67501A YU 67501 A YU67501 A YU 67501A
Authority
YU
Yugoslavia
Prior art keywords
oral administration
racemates
tolperison
pharmaceutical preparation
tolperisone
Prior art date
Application number
YU67501A
Other languages
English (en)
Inventor
Wemer Frantsits
Original Assignee
SANOCHEMIA PHARMAZEUTIKA Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SANOCHEMIA PHARMAZEUTIKA Ag. filed Critical SANOCHEMIA PHARMAZEUTIKA Ag.
Publication of YU67501A publication Critical patent/YU67501A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Farmaceutska kompozicija sa sadržajem tolperisona ili neke njegove soli u obliku racematske smeše, koja može biti u vidu 50/50 racemata ili racemata sa pretežnim udelom (-)-izomera tolperisona. Za oralno davanje odredjena kompozicija formuliše se kao čvrsti ili tečni lek, pri čemu se tolperison nalazi u vidu 50/50 racemata ili racemata sa pretežnim udelom (-)-izomera ili (+)-izomera, koji se produženo ispušta u ljudskom organizmu, preporučljivo u crevnom traktu.
YU67501A 1999-04-01 1999-11-16 Farmaceutska kompozicija sa sadržajem tolperisona za oralno davanje YU67501A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0059499A AT409083B (de) 1999-04-01 1999-04-01 Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung

Publications (1)

Publication Number Publication Date
YU67501A true YU67501A (sh) 2004-07-15

Family

ID=3494723

Family Applications (1)

Application Number Title Priority Date Filing Date
YU67501A YU67501A (sh) 1999-04-01 1999-11-16 Farmaceutska kompozicija sa sadržajem tolperisona za oralno davanje

Country Status (23)

Country Link
US (1) US6500455B1 (sh)
EP (1) EP1165081B1 (sh)
JP (1) JP2002541107A (sh)
AT (1) AT409083B (sh)
AU (1) AU1136400A (sh)
CA (1) CA2366841C (sh)
CZ (1) CZ20013404A3 (sh)
DE (1) DE59912101D1 (sh)
EE (1) EE04833B1 (sh)
ES (1) ES2168241T3 (sh)
HR (1) HRPK20010706B1 (sh)
HU (1) HUP0200669A3 (sh)
IL (2) IL145559A0 (sh)
NO (1) NO20014738L (sh)
NZ (1) NZ514129A (sh)
PL (1) PL197545B1 (sh)
PT (1) PT1165081E (sh)
RU (1) RU2223098C2 (sh)
SK (1) SK13642001A3 (sh)
TR (1) TR200102811T2 (sh)
UA (1) UA71613C2 (sh)
WO (1) WO2000059508A1 (sh)
YU (1) YU67501A (sh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0300929A3 (en) * 2003-04-09 2005-06-28 Richter Gedeon Vegyeszet Analgetic and/or muscle relaxant pharmaceutical composition
DE10341923A1 (de) * 2003-09-11 2005-04-07 Heinl, Alexander, Dr.med. Verwendung von Tolperison
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
DE10359335A1 (de) * 2003-10-23 2005-05-25 Viatris Gmbh & Co. Kg Kombinationen aus Kaliumkanalöffnern und Natriumkanalinhibitoren oder Natriumkanal beeinflussenden Wirkstoffen zur Behandlung von Schmerzzuständen
AT500144A1 (de) * 2004-03-05 2005-11-15 Sanochemia Pharmazeutika Ag Tolperison enthaltende, pharmazeutische zubereitung mit steuerbarer wirkstofffreisetzung zur oralen verabreichung
US20070249673A1 (en) * 2006-04-20 2007-10-25 Angelika Bodenteich Method for administering tolperisone
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
PT2061465E (pt) * 2006-08-23 2013-07-15 Valeant Pharmaceuticals Int Derivados de 4-(n-azacicloalquil)anilidas como moduladores do canal de potássio
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
US8030518B2 (en) 2006-11-28 2011-10-04 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
AT505225A1 (de) 2007-04-26 2008-11-15 Sanochemia Pharmazeutika Ag 0erfahren zur herstellung von hoch reinem 2,4'-dimethyl-3-piperidino-propiophenon (tolperison), dieses enthaltende pharmazeutische zusammensetzungen, sowie tolperison enthaltende wirkstoffformulierungen
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
HUP0700485A3 (en) * 2007-07-23 2010-01-28 Richter Gedeon Nyrt Pharmaceutical composition with controlled release containing tolperisone
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
US20100249423A1 (en) * 2009-03-09 2010-09-30 Sanochemia Pharmazeutika Ag Tolperisone controlled release tablet
CN102438597A (zh) 2009-03-09 2012-05-02 丁内沙·沙蒂尔阿尔·帕特尔 一种选自中枢性作用肌弛缓药类型的化合物的新型缓释制剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5154918A (en) * 1974-10-08 1976-05-14 Nippon Kayaku Kk Jozaino seizoho
JPS5191315A (ja) * 1975-02-06 1976-08-10 Anteinaensantoruperizonshirotsupunoseizoho
JPS5340779A (en) * 1976-09-21 1978-04-13 Nippon Kayaku Co Ltd Optically active tolpertisone, their preparation and pharmaceuticals containting the same
JPS58135806A (ja) * 1982-02-08 1983-08-12 Nippon Kayaku Co Ltd 多層コ−チング製剤
JPS6143108A (ja) * 1984-08-03 1986-03-01 Nippon Shinyaku Co Ltd 医薬品製剤及びその製造法
JPH0637389B2 (ja) * 1986-12-26 1994-05-18 北陸製薬株式会社 頻尿治療剤
JPH0720866B2 (ja) 1987-05-15 1995-03-08 三生製薬株式会社 エペリゾン又はトルペリゾン或いはそれらの塩類含有経皮適用製剤
IL87710A (en) 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
MY115126A (en) * 1990-04-27 2003-04-30 Seikisui Chemical Co Ltd Percutaneously absorbable eperisone or tolperisone preparation.
US5128145A (en) * 1990-06-13 1992-07-07 Alza Corporation Dosage form for Parkinson's disease, spasticity and muscle spasms
TW209174B (sh) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
DE69220317T2 (de) * 1991-10-01 1997-10-16 Takeda Chemical Industries Ltd Mikropartikeln-Zusammenfassung zur verlängerten Freigabe und Herstellung derselbe
US5811547A (en) * 1992-10-14 1998-09-22 Nippon Shinyaju Co., Ltd. Method for inducing crystalline state transition in medicinal substance

Also Published As

Publication number Publication date
HRP20010706A2 (en) 2003-02-28
PL197545B1 (pl) 2008-04-30
HRPK20010706B1 (en) 2004-12-31
ES2168241T1 (es) 2002-06-16
NO20014738L (no) 2001-10-23
ES2168241T3 (es) 2005-11-01
WO2000059508A1 (de) 2000-10-12
RU2223098C2 (ru) 2004-02-10
SK13642001A3 (sk) 2002-03-05
ATA59499A (de) 2001-10-15
IL145559A (en) 2008-12-29
NZ514129A (en) 2003-04-29
EP1165081B1 (de) 2005-05-25
PT1165081E (pt) 2005-08-31
HUP0200669A2 (hu) 2002-07-29
CA2366841C (en) 2008-10-07
AT409083B (de) 2002-05-27
EE200100503A (et) 2003-02-17
HUP0200669A3 (en) 2002-11-28
NO20014738D0 (no) 2001-09-28
PL351377A1 (en) 2003-04-07
CZ20013404A3 (cs) 2002-02-13
IL145559A0 (en) 2002-06-30
CA2366841A1 (en) 2000-10-12
EP1165081A1 (de) 2002-01-02
JP2002541107A (ja) 2002-12-03
EE04833B1 (et) 2007-06-15
US6500455B1 (en) 2002-12-31
UA71613C2 (uk) 2004-12-15
AU1136400A (en) 2000-10-23
TR200102811T2 (tr) 2002-05-21
DE59912101D1 (de) 2005-06-30

Similar Documents

Publication Publication Date Title
YU67501A (sh) Farmaceutska kompozicija sa sadržajem tolperisona za oralno davanje
ATE380023T1 (de) Orale feste pharmazeutische zusammensetzungen zur ph-abhängig mehrphasigen freisetzung
UY26139A1 (es) Composiciones de medicamentos a base de compuestos anticolinérgicamente activos y beta- miméticos
NZ284846A (en) 1-substituted-pyrazolo[3,4-b]pyridin-5-carboxylic acid derivatives, preparation, use, intermediates and pharmaceutical compositions thereof
RU2325389C2 (ru) Композиция и производные замещенного азаиндолоксоацетапиперазина, обладающие противовирусной активностью
FR2639636B1 (fr) Nouveaux composes heterocycliques a activite anticonvulsivante, procede de preparation et compositions therapeutiques les contenant
FR2805818B1 (fr) Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
FR2822826B1 (fr) Nouveaux derives sulfonyles d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP2298416A3 (en) Sustained-release tramadol formulations with 24-hour clinical efficacy
NZ516347A (en) Indanyl-substituted benzenecarboxamides, process for their preparation, their use as a medicament and pharmaceutical formulations containing them
ATE122668T1 (de) Diarylsubstituierte heterocyclische verbindung, ihre herstellung und arzneimittel und kosmetika daraus.
FR2807038B1 (fr) Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant
FR2761066B1 (fr) Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
IL170518A (en) Liquid oral dosage formulations comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino) phenylacetic acid, methods for preparing them and use thereof for the manufacture of medicaments
HUP0204563A3 (en) Process for preparation of 3,3-diarylpropylamine derivatives and their intermediates and their use for preparation of pharmaceutical compositions
FR2846656B1 (fr) Nouveaux derives d'imidazopyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ATE444069T1 (de) Chinolin-derivate zur behandlung von mglur5- rezeptor-vermittelten erkrankungen
NO982904D0 (no) Oral farmas°ytisk sammensetning inneholdende 5-ASA, med modifisert frigj°ring, og fremgangsmÕte for behandling av tarmsykdommer
FR2796380B3 (fr) Nouveaux derives d'aminothiazoles, leur preparation et les compositions pharmaceutiques les contenant
HRP20050831A2 (en) Novel oxazole derivatives, their manufacture and use as pharmaceutical agents
ATE400563T1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
FR2869611B1 (fr) Derives de l'acide hexenoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et applications en therapeutique
TNSN01001A1 (fr) NOUVELLES PYRAZOLO [4,3-e] DIAZEPINES SUBSTITUEES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
FR2782515B1 (fr) NOUVEAUX DERIVES DE L'INDANE-1-Ol, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
EA200101108A1 (ru) Полиморфные модификации кристаллического цитрата азабицикло[2.2.2]октан-3-амина и их фармацевтические композиции